Trial Profile
A randomized phase II trial of sapacitabine in combination with other agents for the treatment of myelodysplastic syndromes
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2016
Price :
$35
*
At a glance
- Drugs Sapacitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 29 Mar 2016 New trial record